Patent intelligence · US
US 10888597
Composition for treating brain stroke
Composition for treating brain stroke
Patent details — US 10888597
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 12, 2021
- Expiration
- Jan 7, 2041
- Applicant
- ENLIVEN BIOTECHNOLOGY CO, LTD.
- Claims
- 9
- CPC classes
- A61K, A61K36/232, A61K36/236, A61K36/258
Quick answer
US 10888597 (Composition for treating brain stroke) is held by ENLIVEN BIOTECHNOLOGY CO, LTD.. Status: granted. Granted Jan 12, 2021. Expires Jan 7, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ENLIVEN BIOTECHNOLOGY CO, LTD.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K36/232, A61K36/236, A61K36/258, A61K36/282, A61K36/355
More from ENLIVEN BIOTECHNOLOGY CO, LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12240846
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted -
US 11807649
Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2
granted -
US 11807638
5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases
granted -
US 11767321
5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
granted
Frequently asked questions
What is US patent 10888597?
US 10888597 (Composition for treating brain stroke) is held by ENLIVEN BIOTECHNOLOGY CO, LTD.. Status: granted. Granted Jan 12, 2021. Expires Jan 7, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10888597?
ENLIVEN BIOTECHNOLOGY CO, LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 10888597 expire?
Our index shows an expiration date of Jan 7, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.